E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Immunotherapy

Background:

• Anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunotherapies are effective for non-small cell lung cancer (NSCLC).
• Understanding PD-L1 regulation is crucial for enhancing treatment efficacy.
• Current knowledge of PD-L1 regulatory mechanisms in NSCLC remains limited.

Purpose of the Study:

• To elucidate novel regulatory pathways of PD-L1 in wild-type epidermal growth factor receptor (EGFR) NSCLC.
• To identify specific molecules involved in PD-L1 inhibition.
• To explore the correlation between these regulatory molecules and PD-L1 expression in NSCLC tissues.

Main Methods:

• Investigated the role of ubiquitin ligases Cbl-b and c-Cbl in wild-type EGFR NSCLC cell lines (A549, H460).
• Assessed the impact of Cbl-b and c-Cbl on STAT, AKT, and ERK signaling pathways.
• Utilized miRNA screening and validation to identify targets of Cbl-b and c-Cbl (miR-181a and miR-940).
• Analyzed the expression correlation between Cbl-b/c-Cbl and PD-L1 in NSCLC patient tissues.

Main Results:

• Cbl-b and c-Cbl were found to inhibit PD-L1 expression by inactivating STAT, AKT, and ERK signaling in wild-type EGFR NSCLC cells.
• MiR-181a was identified as a targeting miRNA for Cbl-b, and miR-940 for c-Cbl.
• A negative correlation was observed between the expression of Cbl-b/c-Cbl and PD-L1 in NSCLC tissues.

Conclusions:

• Cbl-b and c-Cbl represent a novel regulatory mechanism for PD-L1 in wild-type EGFR NSCLC.
• These findings provide a deeper understanding of PD-L1 regulation and potential therapeutic targets.
• The identified regulatory pathway may offer new strategies for improving the efficacy of anti-PD-1/PD-L1 therapies in NSCLC.